iRGD peptide is a 9-amino acid cyclic peptide, triggers tissue penetration of drugs by first binding to av integrins, then proteolytically cleaved in the tumor to produce CRGDK/R to interact with neuropilin-1, and has tumor-targeting and tumor-penetrating properties.
|Solubility (25°C)||Water ≥ 50 mg/mL|
|Storage||-20°C, protect from light, dry, sealed|
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
|Related Integrin Products|
SGN-B6A is an integrin-targeted ADC that selectively targets solid tumors by recognizing ITGB6.
Alintegimod is an orally active variant activator of integrins αLβ2 and α4β1 that enhances T cell activation and adhesion.
OS2966 is a first-in-class (first-in-class) neutralizing anti-CD29 monoclonal antibody that selectively modulates CD29 (integrin b1 subunit) and can be used in glioblastoma-related studies.
JSM-6427 is an integrin α5β1 antagonist.
MORF-057 is an oral small molecule α4β7 integrin (integrin) inhibitor that can be used in studies related to ulcerative colitis (UC).
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.